Commercial Sales Intern
About the job
- Strong time management skills.
- Ability to prioritize, work effectively, meet multiple deadlines, and manage an individual work schedule.
- Ability to quickly become knowledgeable about multiple products, markets, pests, cultural practices, and production technology.
- Interest in helping customers understand, accept, and better utilize company products.
- Ability to work effectively with a variety of people and present ideas clearly in person and in writing.
- A cumulative GPA of 3.0 is prioritized for candidates.
- Applicants must not require visa sponsorship.
- Develop a work plan with a District Sales Leader or Territory Manager mentor, including objectives, expectations, and planned results.
- Work independently, accept accountability, and meet productivity goals.
- Support promotion and new product launches.
- Manage plot tours and trials.
- Conduct customer surveys and collect testimonials.
- Independently analyze product performance.
- Gather and analyze market data for use by a sales district or marketing team.
- Represent company products to customers.
- Participate in training covering company culture, ethics, driver and product safety, products and technical information, agronomy, crop production, selling skills, role playing, and project management.
About the company
Corteva is a global agriculture technology company focused on helping farmers increase yields and protect crops. Its products include Pioneer seeds, crop protection solutions, and digital farming tools, plus gene-editing initiatives to support data-driven decisions. It differentiates itself as a pure-play agriculture company carved from DowDuPont, with a growing move into biologicals and a plan to spin into two independent companies (seeds and crop protection) by 2026. Its goal is to meet the food needs of a growing population with sustainable, profitable farming.
Company Size
10,001+
Company Stage
IPO
Headquarters
Indianapolis, Indiana
Founded
2019
Get referred to Corteva
See people who can refer or advise you
Simplify's Take
What believers are saying
- First-half 2026 sales rose 4% to $11.28 billion, and EBITDA rose 10%.
- Crop protection volume rose 2% despite pricing pressure in Latin America.
- The September 9, 2026 Globachem JV extends product development into the early 2030s.
What critics are saying
- FTC settlement bars loyalty programs for ten years and forces a $35 million payment.
- Fifteen states sued on October 1, 2026, alleging Vylor hid PFAS liabilities.
- Latin America price declines already compressed crop protection margins, and they hit 2027 earnings.
What makes Corteva unique
- Post-October 1, 2026, Corteva is a pure-play crop protection company with $11 billion pipeline.
- Pioneer and global distribution still give Corteva unmatched farmer access across 110 countries.
- Its 12 planned actives, including five biologicals, separate it from generic pesticide sellers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%Corteva completed the spin-off of its seed and genetics business, Vylor, on Thursday. Shareholders received one Vylor share for every Corteva share held as of 24 September. Following the separation, CTVA's market capitalisation fell by over $42 billion, with shares dropping 83% to a record low. Corteva announced the split a year ago, citing different market evolutions for seed and crop-protection businesses. The company now focuses solely on crop protection, with a pipeline valued at around $11 billion. It targets standalone sales of $8.4 billion to $8.7 billion by 2029. Vylor began trading under ticker VYLR, opening at $66. The seed company holds a $19 billion technology pipeline and expects net sales of $11.2 billion to $11.9 billion by 2029.
Ascribe Bioscience launches Phytalix in Brazil with novel biochemical mode of action. Sep. 29, 2026 Ascribe Bioscience United States follow. US agricultural biotechnology company Ascribe Bioscience has launched Phytalix(R) in Brazil, marking the global commercial debut of the technology following regulatory approvals from Brazil's Ministry of Agriculture and Livestock (MAPA), National Health Surveillance Agency (Anvisa) and Brazilian Institute of Environment and Renewable Natural Resources (IBAMA). Founded in 2017, based upon research conducted at the Boyce Thompson Institute at Cornell University, Ascribe selected Brazil as the first commercial market for Phytalix, reflecting the country's role as a major testing and scale-up platform for biological and biochemical crop protection technologies. "The launch of Phytalix(R) brings Brazilian growers a powerful and sustainable new tool to strengthen plant defenses against major soybean and corn diseases. This revolutionary new molecule demonstrates that preventive crop protection, without harming the environment, can enhance fungicide performance within application programs that growers are already familiar with," said Gabriel Wilmoth, chief operating officer at Ascribe Bioscience. Soil science applied to crop immunity Unlike conventional chemical and microbial crop protection products that directly target pathogens, Phytalix is designed to act preventively by stimulating metabolic pathways and activating the plant's natural defense mechanisms. The Phytalix technology is based on an ascaroside, a compound associated with the soil microbiome that is synthesized under controlled laboratory conditions. According to Ascribe, the molecule primes the crop's immune system for a rapid response, while actual activation of defense barriers occur when the plant detects an invading pathogen. This mechanism is intended to avoid unnecessary energy expenditure by the plant, while enabling a faster defense response against disease pressure. Phytalix has also received its own resistance classification from the Fungicide Resistance Action Committee (FRAC), according to Ascribe. The classification places the technology in a new mode-of-action category and is intended to support resistance-management strategies and rotation of modes of action in crop protection programs. Biological technology with conventional operational profile A key feature of Phytalix is its operational stability, which the company says addresses some of the logistical constraints traditionally associated with biological crop protection products. Additionally, the Phytalix technology offers shelf stability and tolerance to temperature fluctuations, including heat and cold, as well as ultraviolet radiation. This allows it to be incorporated into existing farm application systems and machinery without requiring major operational changes. Phytalix was developed primarily for Brazil's soybean-corn production system and has also generated positive results in trials involving rice, coffee and cotton. Following five years of validation, Ascribe says Phytalix has been evaluated in more than 450 field trials across major agricultural regions, including Mato Grosso, Mato Grosso do Sul, Paraná, Rio Grande do Sul, São Paulo, Bahia, Goiás and Minas Gerais. According to Ascribe, the trials demonstrated Phytalix's efficacy against major soybean diseases, including brown spot, target spot and Asian soybean rust, as well as white spot and Bipolaris leaf spot in corn. Ascribe expects growers to generate additional commercial-scale productivity data during the 2026/27 season. "Phytalix(R) is the result of global science, independently validated by renowned researchers in Brazil and worldwide. Its versatility allows direct integration into resistance-management programs, reducing phytotoxicity and enhancing disease control with each application," said Edison Hidalgo, Ascribe's research and development manager in Brazil. Ascribe also said the molecule has been evaluated under a broad range of Brazilian climatic conditions and demonstrated a safety profile for growers, farm workers, consumers, pollinators, beneficial insects and soil biology. Global investment and Brazilian operation Ascribe Bioscience was founded by scientist Frank Schroeder and executive Jay Farmer. Ascribe recently raised US$12 million in investment, led by Corteva through Corteva Catalyst and Acre Venture Partners, with participation from Syngenta Group Ventures and other global agtech investors. To support its Brazilian commercial operation, Ascribe has established a local technical structure, with formulation and filling carried out in Brazil through strategic partners. Production of the active ingredient remains centralized in the United States. (Editing by Leonardo Gottems, reporter for AgroPages)
Corteva reaches $35 million settlement over alleged monopoly violations. Iowa is expected to receive about $2.4 million from a $35 million settlement with pesticide maker Corteva in a federal antitrust case. The Federal Trade Commission (FTC) and a bipartisan group of states, including Iowa, accused Corteva of using loyalty payments to encourage distributors to limit sales of competing products, including lower-cost generic pesticides. The agencies argued the practice restricted competition and artificially inflated chemical prices for farmers. Under the proposed settlement, Corteva would dismantle its existing loyalty program and face 10 years of restrictions on payments tied to distributors' purchases of its products over generic alternatives. Iowa Attorney General Brenna Bird, who joined the settlement on Iowa's behalf, says, "This is a great win for Iowa farmers, but also for all Iowans, Higher input prices for farmers growing our food mean higher prices at the grocery store. Iowa farmers and families deserve a marketplace without inflated prices." The settlement resolves the government's claims against Corteva, but a joint suit against fellow pesticide maker Syngenta is still pending. The agreement is separate from an $85 million proposed settlement of a class-action lawsuit involving more than 100,000 farmers. A link to the full settlement agreement is included with this story on its website.
Corteva's Drew Ratterman Receives MACA's Highest Award | Published on: Sep 21, 2026
Corteva and Belgium's Globachem N.V. announced a definitive agreement on 9 September to form a 50/50 joint venture developing crop protection products for Europe and the Americas. The deal comes ahead of Corteva's crop protection business spinning off as standalone company Vylor on 1 October. The venture builds on an existing relationship, combining Corteva's late-pipeline technology with Globachem's formulation expertise. New products aren't expected until the early 2030s, pending regulatory approval targeted for Q4 2026. Corteva's first-half 2026 net sales rose 4% to $11.28 billion, with operating EBITDA up 10% to $3.70 billion. However, crop protection segment pricing declined 3% in the first half due to competitive pressure in Latin America, despite a 2% volume increase.